Prothena Corporation plc PRTA R2K

Healthcare · Biotechnology · Ireland

https://www.prothena.com

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Market & Price

Market Cap

$532.96M

Current Price

$10.18

High / Low (52W)

$11.51 / $4.59

Beta

-0.23

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$5.89

Price to Book

1.73

P/S

9.20

EV/EBITDA

-2.29

Dividend Yield

Profitability & Returns

ROCE

-64.54%

ROE

-40.30%

ROA

-13.78%

Profit Margin

Op Margin

50.49%

EPS (Latest Qtr)

$0.60

EPS (TTM)

$-2.81

Balance Sheet & Liquidity

Debt/Equity

2.45

Quick Ratio

10.13

Current Ratio

10.43

Debt

$7.65M

Total Assets

$326.80M

Current Assets

$315.19M

Working Capital

$274.35M

Ownership

Promoter Holding

20.24%

Chg in Prom Hold

FII / Inst Holding

90.69%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$211.15M

Total Revenue (TTM)

$57.94M

EBITDA

$-92.33M

Free Cash Flow

$-31.58M

Operating Cash Flow

$-81.34M

Shares Outstanding

52.35M

Gross Margin

-66.84%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-43.57%

Profit 5Y

-36.24%

Revenue (YoY)

1,706.40%

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -43.6% CAGR over 5 years.
Earnings shrank at -36.2% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PRTA Prothena Corporation plc R2K	10.18	-	$532.96M	-	-64.54%	-40.30%	-43.57%	-36.24%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	186.00K	167.00K	205.00K	256.00K	141.00K	195.00K	157.00K	360.00K	160.00K	60.07M	139.17M	1.15M	1.31M	1.52M	2.17M	4.02M	84.87M	50.00K	132.01M	-	2.83M	4.42M	2.42M	21.00K	51.08M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	68.41M	56.43M	42.18M	27.23M	25.29M
Operating Income	-18.04M	-22.66M	-	-27.41M	-40.16M	-42.69M	-	-36.27M	-18.13M	-53.53M	-	-48.71M	-63.07M	-24.32M	-	-22.95M	-18.50M	-20.97M	-	-24.85M	-26.73M	-30.85M	-	-32.11M	27.95M	109.23M	-37.94M	-43.21M	-50.33M	-56.33M	-66.50M	10.31M	-81.53M	58.38M	-	-65.58M	-52.01M	-39.76M	-27.21M	25.79M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-65.36M	-51.78M	-39.53M	-26.99M	25.98M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-61.37M	-80.97M	-36.91M	-21.58M	32.72M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.18M	44.80M	-371.00K	10.00K	1.00K
Net Income	-18.28M	-22.98M	-24.16M	-27.52M	-40.45M	-43.24M	-48.90M	-35.38M	-17.70M	-52.39M	-47.76M	-48.74M	-59.88M	-24.56M	-22.46M	-20.86M	-15.81M	-19.45M	-21.55M	-23.57M	-26.28M	-30.58M	-30.72M	-36.73M	27.64M	109.25M	-36.29M	-41.24M	-45.76M	-46.86M	-54.59M	21.91M	-72.24M	66.89M	-	-60.20M	-125.77M	-36.54M	-21.59M	32.72M
Diluted EPS	-0.59	-0.73	-0.76	-0.81	-1.18	-1.26	-1.41	-0.99	-0.46	-1.37	-1.24	-1.26	-1.50	-0.62	-0.56	-0.52	-0.40	-0.49	-0.54	-0.59	-0.66	-0.77	-0.77	-0.91	0.58	2.13	-0.78	-0.88	-0.97	-0.89	-1.03	0.38	-1.34	1.22	-	-1.12	-2.34	-0.68	-0.40	0.60
R&D Expense	12.79M	17.18M	-	20.49M	32.36M	26.84M	-	25.70M	34.03M	41.31M	-	34.71M	31.45M	18.52M	-	13.30M	9.58M	12.49M	-	15.25M	17.27M	21.61M	-	21.14M	21.09M	17.99M	27.26M	31.57M	39.86M	44.76M	56.01M	57.91M	64.11M	57.51M	50.72M	50.81M	40.52M	28.94M	-	12.63M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	955.00K	814.00K	853.00K	-	53.91M	91.37M	135.16M	9.68M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	185.46M	282.41M	289.72M	194.24M
Operating Income	-29.24M	-41.41M	-40.43M	-6.65M	-79.94M	-159.53M	-155.25M	-158.85M	-85.70M	-112.73M	-	-131.56M	-191.04M	-154.56M	-184.56M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-130.81M	-190.11M	-153.67M	-183.66M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-125.61M	-160.48M	-128.93M	-200.83M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-8.66M	-13.45M	-6.62M	43.26M
Net Income	-29.67M	-41.41M	-41.00M	-7.15M	-80.61M	-160.11M	-153.24M	-155.65M	-77.68M	-111.14M	-	-116.95M	-147.03M	-122.31M	-244.09M
Diluted EPS	-	-	-	-	-	-	-	-	-1.95	-2.78	-	-2.47	-2.76	-2.27	-4.53
R&D Expense	24.17M	34.14M	26.05M	38.45M	58.44M	119.53M	134.55M	101.18M	50.84M	74.88M	82.28M	135.56M	220.57M	222.52M	134.85M

Compounded Sales Growth

5 Years:	-43.57%
1 Year:	1,706.40%

Compounded Profit Growth

5 Years:	-36.24%
1 Year:	-

Stock Price Performance

1 Year:	+121.79%
6 Months:	-3.05%
3 Months:	+17.42%
1 Month:	-6.35%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	129.28M	182.41M	304.12M	385.24M	459.98M	496.33M	498.80M	419.27M	332.98M	-	758.03M	696.38M	547.11M	326.80M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	719.10M	639.28M	485.41M	315.19M
Cash & Equivalents	0	0	124.86M	176.68M	293.58M	370.59M	386.92M	417.62M	427.66M	375.72M	295.38M	-	710.41M	618.83M	471.39M	307.53M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	13.00K	0	5.16M	0	-
Total Liabilities	-	-	2.80M	9.14M	14.23M	24.57M	94.57M	89.14M	175.80M	146.35M	148.97M	-	135.99M	135.02M	60.18M	46.33M
Current Liabilities	-	-	1.74M	7.41M	12.04M	22.22M	41.08M	37.37M	14.93M	17.71M	25.85M	-	50.15M	56.89M	48.50M	40.84M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	6.47M	11.84M	10.84M	8.37M
Total Equity	-	-	126.48M	173.27M	289.89M	360.67M	365.40M	407.19M	323.00M	272.92M	184.01M	-	622.04M	561.37M	486.93M	280.47M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	52.10M	53.68M	53.83M	53.83M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-19.70M	-42.07M	-32.10M	-683.00K	-58.60M	-116.25M	-131.18M	-28.28M	-52.97M	-80.36M	-	-108.82M	-133.91M	-150.05M	-163.58M
Investing Cash Flow	-595.00K	-1.30M	-535.00K	-499.00K	-1.38M	-16.64M	-3.52M	-1.73M	-547.00K	-196.00K	-	-464.00K	-2.77M	-298.00K	-138.00K
Financing Cash Flow	20.29M	168.23M	84.45M	118.08M	136.99M	153.29M	165.40M	40.04M	228.00K	215.00K	-	241.46M	45.10M	1.55M	-139.00K
Capital Expenditure	-	-	-	-	-	-	-	-	-	-	-	-464.00K	-2.81M	-298.00K	-138.00K
Free Cash Flow	-	-	-	-	-	-	-	-	-	-	-	-109.28M	-136.72M	-150.35M	-163.72M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	132.17M	-91.58M	-148.79M	-163.86M

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-16,634.0%	-10,527.9%	-13,216.2%	-	-244.1%	-209.1%	-114.4%	-1,905.8%
Net Margin %	-	-	-	-	-	-	-	-16,297.9%	-9,542.6%	-13,029.8%	-	-217.0%	-160.9%	-90.5%	-2,520.6%
ROE %	-	-32.7%	-23.7%	-2.5%	-22.4%	-43.8%	-37.6%	-48.2%	-28.5%	-60.4%	-	-18.8%	-26.2%	-25.1%	-87.0%
ROCE %	-	-32.5%	-23.1%	-2.3%	-22.0%	-38.1%	-33.8%	-32.8%	-21.3%	-36.7%	-	-18.6%	-29.9%	-31.0%	-64.5%

Shareholding Pattern

Insiders

20.24%

Institutions

90.69%

Public Float

113.71%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	FMR, LLC	14.42%	7.55M	$76.87M
2	Rubric Capital Management LP	9.55%	5.00M	$50.90M
3	Blackrock Inc.	8.87%	4.64M	$47.28M
4	State Street Corporation	3.70%	1.94M	$19.73M
5	Shaw D.E. & Co., Inc.	3.37%	1.76M	$17.95M
6	Adar1 Capital Management, LLC	3.02%	1.58M	$16.10M
7	Acadian Asset Management. LLC	2.96%	1.55M	$15.75M
8	Vanguard Portfolio Management LLC	2.76%	1.45M	$14.72M
9	Morgan Stanley	2.35%	1.23M	$12.53M
10	Palo Alto Investors Lp	2.31%	1.21M	$12.30M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PRTA

No recent headlines available.

PRTA · Healthcare